
A leading medical device company helping migraine patients find real-time relief wanted to add secure cellular tracking to support insurance reimbursement and monitor patient use. The challenge: doing so without altering the device’s design or restarting the FDA approval process.
Partnering with Altair, F3 Wireless integrated the ALT1250 chipset to add low-power LTE-M/NB-IoT connectivity and built-in location tracking. The result is a compact, energy-efficient device that connects seamlessly to the cloud for effortless data reporting—preserving FDA clearance and saving months of regulatory time and cost.
Altair ALT1250 modem allows the migraine therapy device to automatically log each session and send secure updates to the cloud— meeting insurance requirements for adherence tracking and unlocking reimbursement eligibility.
Every therapy session is logged and securely transmitted to the cloud. Insurance companies receive the information they need to approve reimbursement without any manual reporting from patients or providers. The device handles documentation automatically.
With cloud-based reporting, healthcare providers can easily see how patients are using the device. This visibility means providers can reach out if patients aren’t using the device as prescribed, and provides objective data to assess treatment success.
The ALT1250's ultra-low power architecture means that cellular features operate within the existing energy budget. Patients still enjoy multiple therapy sessions between charges, so added connectivity doesn’t come at the cost of convenience.
ALT1250 and HL7800 SDK deliver a secure framework designed specifically for connected medical devices handling protected health information.
Cellular Integration Within FDA Constraints
Miniaturized Cellular Integration
Medical Device Connectivity that Pays
for Itself
Altair and F3 Wireless added cellular connectivity without redesigning the device, preserving the original enclosure and tooling. This avoided new FDA testing, kept the launch on schedule, and saved months of development time.
Energy targets were met thanks to the ALT1250's ultra-low-power architecture, so patients still get multi‑day therapy sessions between charges. Automatic data uploads now meet insurance payer requirements, unlocking a reimbursement pathway and expanding the device's market potential.
The result is a connected medical device that delivers secure, compliant cellular connectivity while staying within FDA-cleared hardware constraints—enabling new business models without the risk or cost of a full product redesign.